Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Metabolic syndrome consists of a group of co-occuring conditions that increase an
individual's risk of developing heart disease, stroke, and diabetes. The purpose of this
study is to evaluate the short-term effectiveness of chloroquine, a protein-activation
medication, at improving metabolic syndrome.